Masimo Performance degli utili passati
Criteri Il passato verificati 5/6
Gli utili di Masimo sono diminuiti a un tasso medio annuo di -32.3%, mentre il settore Medical Equipment ha visto gli utili crescere a un tasso medio annuo di 13.6%. I ricavi sono cresciuti crescere a un tasso medio annuo di 5.8%. Il ritorno sul capitale proprio di Masimo è 27.5% e ha margini netti di 13.9%.
Informazioni chiave
-32.28%
Tasso di crescita degli utili
-31.48%
Tasso di crescita dell'EPS
| Medical Equipment Crescita del settore | 8.90% |
| Tasso di crescita dei ricavi | 5.75% |
| Rendimento del capitale proprio | 27.48% |
| Margine netto | 13.91% |
| Ultimo aggiornamento sugli utili | 04 Apr 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • May 12
MASI: Cash Deal Terms And Legal Outcomes Will Shape Future Returns
Analysts held Masimo's fair value estimate steady at $180 per share, with only small tweaks to discount rate, growth, margin, and P/E assumptions as they factor in the agreed $180 per share cash acquisition by Danaher and recent shifts in research coverage and ratings. Analyst Commentary Recent research coverage on Masimo has shifted toward a more balanced stance after the agreed cash acquisition by Danaher at US$180 per share, with several firms resetting ratings and price targets around the deal terms.Aggiornamento della narrazione • Apr 23
MASI: Danaher Cash Offer And Legal And Deal Completion Risks Will Dominate
The analyst fair value estimate for Masimo has been adjusted from $177 to $180, with analysts pointing to the agreed $180 per share cash acquisition by Danaher as the key anchor for updated price targets and ratings. Analyst Commentary Recent research on Masimo has shifted from growth driven valuation debates to a focus on the agreed US$180 per share cash offer from Danaher as the primary reference point for fair value and ratings.Aggiornamento della narrazione • Apr 09
MASI: Danaher Cash Offer And Legal Outcomes Will Steer Deal Path
The analyst price target for Masimo has been trimmed by about $1.60 to $177.00, as analysts factor in a slightly higher discount rate and a modestly lower future P/E, while aligning expectations with the $180 per share cash acquisition offer from Danaher. Analyst Commentary Recent research on Masimo has become highly focused on the agreed cash acquisition by Danaher at $180 per share, with most coverage shifting from long term growth narratives to deal related outcomes and near term valuation anchor points.Aggiornamento della narrazione • Mar 25
MASI: Danaher Cash Offer And Patent Rulings Will Shape Deal Outcome
Analysts kept Masimo's fair value estimate steady at $178.60 while aligning their price targets around the agreed $180 per share cash acquisition by Danaher, with recent rating changes reflecting the view that any potential upside is now largely tied to the deal closing as planned. Analyst Commentary Recent research on Masimo centers on the agreed US$180 per share cash offer from Danaher, with ratings and targets now clustered around that level.Aggiornamento della narrazione • Mar 05
MASI: Danaher Cash Deal And Legal Overhang Will Frame Future Returns
The updated analyst price target for Masimo edges down by $0.15 to $178.60, as analysts anchor their views to Danaher's agreed $180 per share cash acquisition and recent rating moves to Neutral or No Rating. Analyst Commentary Recent research around Masimo has centered on the agreed US$180 per share cash acquisition by Danaher, with most analysts reframing their views around deal completion rather than standalone upside or downside.Aggiornamento della narrazione • Feb 18
MASI: Danaher Cash Buyout Will Define Future Returns And Key Risks
Analysts have trimmed their Masimo fair value estimate from $183.13 to $178.75 to align expectations with the agreed $180 per share cash acquisition by Danaher. This shift is reflected in new Hold and Neutral ratings that are centered around the $180 level.Seeking Alpha • Feb 17
Masimo: Danaher Acquisition Saves The Company From Lackluster Performance
Summary Masimo Corporation agreed to be acquired by Danaher for $180/share, valuing MASI at $9.9B. The acquisition offers a strong strategic fit, combining MASI's non-invasive oximetry with DHR's invasive diagnostics for comprehensive acute care solutions. Shareholders benefit from a 34% stock price surge and a potential 2.8% spread to deal close, with minimal market risk. Holding MASI shares until the deal closes offers a relatively safe, low-stress return, though opportunity cost and regulatory risk remain. Read the full article on Seeking AlphaAggiornamento della narrazione • Nov 21
MASI: Renewed Philips Partnership Will Drive Outperformance Despite Market Challenges
Analysts have adjusted their price target for Masimo downward from approximately $188 to $183. This change is attributed to shifts in revenue growth estimates and a strengthening profit margin following recent partnership developments and ongoing market challenges.Articolo di analisi • Sep 12
Is Masimo Corporation (NASDAQ:MASI) Potentially Undervalued?
Masimo Corporation ( NASDAQ:MASI ), might not be a large cap stock, but it received a lot of attention from a...Articolo di analisi • Aug 01
Calculating The Fair Value Of Masimo Corporation (NASDAQ:MASI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Masimo fair value estimate is US$136 Masimo's US$154 share...Articolo di analisi • Jun 19
Is Masimo (NASDAQ:MASI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • May 29
Is It Time To Consider Buying Masimo Corporation (NASDAQ:MASI)?
Masimo Corporation ( NASDAQ:MASI ), is not the largest company out there, but it saw significant share price movement...Seeking Alpha • Apr 25
Masimo: Priced Dearly Given Uncertainty
Summary Masimo Corporation, a mid-cap healthcare firm, has a new CEO and is navigating considerable uncertainty. Some aspects of the company's divestiture of its consumer business are still unclear. Despite this, the stock is generally well liked within the analyst firm community, following solid Q4 results. An analysis around Masimo Corporation follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Masimo: A Stellar Performance After The Dust Has Settled
Summary Masimo's proxy fight and Sound United acquisition distracted from the core business, but resolution and focus on healthcare are driving value and momentum. Shares surged over 50% since July due to strong Q2 results and improved earnings guidance, despite ongoing challenges and leadership changes. Current valuations are demanding, suggesting an opportune time for profit taking, while I maintain a position for long-term growth potential. Divesting Sound United could reduce debt, enhancing focus on the core med-tech business with promising double-digit organic growth. Read the full article on Seeking AlphaSeeking Alpha • Sep 25
Masimo Corporation: Too Much Uncertainty For Now
Summary Masimo Corporation's stock has underperformed, with shares down 6% versus SPY's 15% increase, due to mixed margins and lack of meaningful catalysts. The company's financials show low ROA, ROE, and ROTC, with tight margins and a concerning interest coverage ratio of 2.6x. The sale of Sound United and recent partnerships with Google and Qualcomm offer potential, but the future growth sustainability remains uncertain. Internal management struggles and recent board shakeup add to the volatility, making me cautious and opting to stay on the sidelines for now. Read the full article on Seeking Alpha
Nuova narrazione • Aug 28
Sensors Surge And Decisive Shifts Set To Soar In Healthcare Triumph
Increased hospital admissions and successful hospital conversions to Masimo products are anticipated to continue driving healthcare revenue growth.Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Masimo guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 04 Apr 26 | 1,559 | 217 | 517 | 123 |
| 03 Jan 26 | 1,527 | 208 | 511 | 126 |
| 27 Sep 25 | 2,182 | -240 | 749 | 203 |
| 28 Jun 25 | 2,154 | -270 | 770 | 210 |
| 29 Mar 25 | 1,428 | 31 | 516 | 142 |
| 28 Dec 24 | 1,395 | 16 | 518 | 146 |
| 28 Sep 24 | 1,576 | 115 | 538 | 152 |
| 29 Jun 24 | 1,711 | 101 | 558 | 161 |
| 30 Mar 24 | 1,823 | 92 | 588 | 163 |
| 30 Dec 23 | 1,276 | 108 | 451 | 131 |
| 30 Sep 23 | 2,116 | 89 | 690 | 192 |
| 01 Jul 23 | 2,187 | 116 | 707 | 198 |
| 01 Apr 23 | 2,297 | 118 | 728 | 206 |
| 31 Dec 22 | 2,036 | 144 | 641 | 191 |
| 01 Oct 22 | 1,746 | 171 | 559 | 170 |
| 02 Jul 22 | 1,505 | 191 | 487 | 153 |
| 02 Apr 22 | 1,244 | 223 | 408 | 139 |
| 01 Jan 22 | 1,239 | 230 | 395 | 137 |
| 02 Oct 21 | 1,207 | 232 | 382 | 136 |
| 03 Jul 21 | 1,177 | 224 | 371 | 129 |
| 03 Apr 21 | 1,173 | 229 | 376 | 126 |
| 02 Jan 21 | 1,144 | 240 | 369 | 119 |
| 26 Sep 20 | 1,096 | 223 | 361 | 110 |
| 27 Jun 20 | 1,047 | 222 | 351 | 106 |
| 28 Mar 20 | 976 | 211 | 330 | 99 |
| 28 Dec 19 | 938 | 196 | 315 | 93 |
| 28 Sep 19 | 913 | 190 | 306 | 91 |
| 29 Jun 19 | 895 | 198 | 297 | 87 |
| 30 Mar 19 | 877 | 197 | 289 | 83 |
| 29 Dec 18 | 858 | 194 | 285 | 81 |
| 29 Sep 18 | 843 | 139 | 290 | 76 |
| 30 Jun 18 | 826 | 118 | 284 | 71 |
| 31 Mar 18 | 807 | 119 | 280 | 67 |
| 30 Dec 17 | 790 | 125 | 273 | 65 |
| 30 Sep 17 | 766 | 348 | 271 | 60 |
| 01 Jul 17 | 740 | 340 | 263 | 61 |
| 01 Apr 17 | 720 | 325 | 260 | 59 |
| 31 Dec 16 | 713 | 311 | 255 | 58 |
| 01 Oct 16 | 672 | 109 | 255 | 58 |
| 02 Jul 16 | 657 | 101 | 257 | 57 |
| 02 Apr 16 | 640 | 90 | 254 | 55 |
| 02 Jan 16 | 623 | 83 | 253 | 56 |
| 03 Oct 15 | 623 | 80 | 244 | 58 |
| 04 Jul 15 | 613 | 76 | 246 | 58 |
Guadagni di qualità: MASI ha guadagni di alta qualità.
Margine di profitto in crescita: Gli attuali margini di profitto netti di MASI (13.9%) MASI sono più alti rispetto allo scorso anno (0.8%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di MASI sono diminuiti del 32.3% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di MASI nell'ultimo anno ( 1792.8% ) supera la media quinquennale ( -32.3% all'anno).
Guadagni vs Settore: La crescita degli utili MASI nell'ultimo anno ( 1792.8% ) ha superato la percentuale del settore Medical Equipment 14.8%.
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 27.5% ) di MASI è considerato alto.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 09:12 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/04/04 |
| Utili annuali | 2026/01/03 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Masimo Corporation è coperta da 22 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Michael Polark | Baird |
| Charley Jones | Barrington Research Associates, Inc. |
| Ravi Misra | Berenberg |